Faruqi & Faruqi, LLP, a prominent national securities law firm, has initiated an investigation into potential claims involving investors of **Jasper Therapeutics, Inc.** This inquiry arises from allegations of misleading statements made by the company, which trades on the NASDAQ under the symbol **JSPR**. Investors who acquired securities in Jasper between **November 30, 2023**, and **July 3, 2025**, are encouraged to reach out to the firm to discuss their options.
According to a press release dated **November 8, 2025**, the firm is actively seeking investors who may have suffered financial losses related to Jasper. **James (Josh) Wilson**, a partner at Faruqi & Faruqi, urges affected investors to contact him directly at **877-247-4292** or **212-983-9330 (Ext. 1310)**. The firm also has a deadline of **November 18, 2025**, for investors interested in assuming the role of lead plaintiff in a federal securities class action against Jasper.
The underlying complaint alleges that **Jasper** and its executives breached federal securities laws by failing to disclose critical information. Specifically, the company purportedly lacked proper controls and procedures to ensure that the third-party manufacturers it relied on were compliant with current Good Manufacturing Practices (cGMP). This oversight raised concerns about the validity of ongoing clinical trials and the regulatory prospects of its key product, **briquilimab**.
On **July 7, 2025**, Jasper issued a press release that detailed issues impacting the **BEACON Study**. The statement revealed that results from certain dose cohorts were compromised due to problems with a specific drug product lot. The announcement further disclosed that this lot had also affected participants in the **ETESIAN Study**. Consequently, Jasper announced a halt to the study and the suspension of development for asthma treatment, alongside a restructuring plan aimed at reducing costs.
Following the disclosure of this information, Jasper’s stock price experienced a sharp decline. The share price fell by **$3.73**, or **55.1%**, closing at **$3.04** per share on the same day.
Jasper’s financial and operational challenges cast doubt on the company’s previous assertions of a strong balance sheet and financial stability. The firm has indicated that it will implement cost-cutting measures, including potential restructuring, to extend its financial runway.
Investors who are part of the putative class have the option to move the court to serve as lead plaintiff, or they may choose to remain absent. Participation in any recovery is not contingent upon the decision to take on the lead plaintiff role.
Faruqi & Faruqi also invites anyone with relevant information regarding Jasper’s conduct, including whistleblowers and former employees, to reach out. Additional details regarding the class action can be found on the firm’s website at **www.faruqilaw.com/JSPR**.
This investigation underscores the importance of transparency in corporate communications and the potential ramifications for companies that fail to meet regulatory standards. As this situation develops, the firm remains committed to assisting affected investors in navigating their legal options.
